UBS raised the firm’s price target on Qiagen (QGEN) to $52 from $50 and keeps a Neutral rating on the shares. Qiagen’s portfolio holds several attractive growth drivers including Quantiferon and Qiastat, but the base business will likely deliver lower growth vs. peers, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QGEN:
- Qiagen: Slower Core Growth and Back-Half-Loaded Targets Keep Risk/Reward Balanced at Hold
- QIAGEN Earnings Call: Growth Pillars Offset Near-Term Drag
- Qiagen price target raised to $53 from $48.42 at Baird
- Qiagen price target raised to $53 from $48 at TD Cowen
- Qiagen price target raised to $50 from $45 at Stifel